ABT vs. TEVA: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ABT and TEVA, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ABT dominates in value with a market cap of 231.49 billion USD, eclipsing TEVA’s 18.96 billion USD by roughly 12.21×.
With betas of 0.74 for ABT and 0.63 for TEVA, both show similar volatility profiles relative to the overall market.
TEVA is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ABT, which is purely domestic.
| Symbol | ABT | TEVA |
|---|---|---|
| Company Name | Abbott Laboratories | Teva Pharmaceutical Industries Limited |
| Country | US | IL |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Drug Manufacturers - Specialty & Generic |
| CEO | Mr. Robert B. Ford | Mr. Richard D. Francis |
| Price | 133.05 USD | 16.55 USD |
| Market Cap | 231.49 billion USD | 18.96 billion USD |
| Beta | 0.74 | 0.63 |
| Exchange | NYSE | NYSE |
| IPO Date | March 17, 1980 | February 16, 1982 |
| ADR | No | Yes |
Performance Comparison
This chart compares the performance of ABT and TEVA over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ABT and TEVA based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- TEVA shows a negative P/E of -14.61, highlighting a year of losses, whereas ABT at 17.22 trades on solid profitability.
- TEVA shows a negative forward PEG of -1.13, signaling expected earnings contraction, while ABT at 1.73 maintains analysts’ projections for stable or improved profits.
| Symbol | ABT | TEVA |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 17.22 | -14.61 |
| Forward PEG Ratio (TTM) | 1.73 | -1.13 |
| Price-to-Sales Ratio (P/S, TTM) | 5.47 | 1.14 |
| Price-to-Book Ratio (P/B, TTM) | 2.48 | 3.00 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 34.77 | 24.73 |
| EV-to-EBITDA (TTM) | 22.97 | 23.01 |
| EV-to-Sales (TTM) | 5.63 | 2.06 |
| EV-to-Free Cash Flow (TTM) | 35.78 | 44.66 |
Dividend Comparison
ABT delivers a 1.71% dividend yield, blending income with growth, whereas TEVA appears to retain its profits, possibly to fund operations, R&D, or other growth initiatives.
| Symbol | ABT | TEVA |
|---|---|---|
| Dividend Yield (TTM) | 1.71% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ABT and TEVA, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- TEVA posts a quick ratio of 0.74, indicating limited coverage of short-term debts from its most liquid assets—while ABT at 1.27 enjoys stronger liquidity resilience.
- TEVA’s low interest coverage (0.44) means it doesn't cover interest from operating earnings. ABT (at 15.39) meets its interest obligations.
| Symbol | ABT | TEVA |
|---|---|---|
| Current Ratio (TTM) | 1.78 | 1.03 |
| Quick Ratio (TTM) | 1.27 | 0.74 |
| Debt-to-Equity Ratio (TTM) | 0.14 | 2.71 |
| Debt-to-Assets Ratio (TTM) | 0.16 | 0.44 |
| Interest Coverage Ratio (TTM) | 15.39 | 0.44 |